1241833-10-2Relevant academic research and scientific papers
Design, synthesis, and in?vitro evaluation of BP-1-102 analogs with modified hydrophobic fragments for STAT3 inhibition
Oleksak, Patrik,Psotka, Miroslav,Vancurova, Marketa,Sapega, Olena,Bieblova, Jana,Reinis, Milan,Rysanek, David,Mikyskova, Romana,Chalupova, Katarina,Malinak, David,Svobodova, Jana,Andrys, Rudolf,Rehulkova, Helena,Skopek, Vojtech,Ngoc Lam, Pham,Bartek, Jiri,Hodny, Zdenek,Musilek, Kamil
, p. 410 - 424 (2021/02/05)
Twelve novel analogs of STAT3 inhibitor BP-1-102 were designed and synthesised with the aim to modify hydrophobic fragments of the molecules that are important for interaction with the STAT3 SH2 domain. The cytotoxic activity of the reference and novel co
2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS
-
Paragraph 00752; 00757; 00884; 00887, (2018/08/20)
The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.
SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS
-
Paragraph 0090, (2015/12/17)
The present disclosure relates to compounds having the Formula (Formula (I)) which are inhibitors of STAT5.
Nanomolar-potency small molecule inhibitor of STAT5 protein
Cumaraswamy, Abbarna A.,Lewis, Andrew M.,Geletu, Mulu,Todic, Aleksandra,Diaz, Diego B.,Cheng, Xin Ran,Brown, Carla E.,Laister, Rob C.,Muench, David,Kerman, Kagan,Grimes, H. Leighton,Minden, Mark D.,Gunning, Patrick T.
, p. 1202 - 1206 (2015/04/27)
We herein report the design and synthesis of the first nanomolar binding inhibitor of STAT5 protein. Lead compound 13a, possessing a phosphotyrosyl-mimicking salicylic acid group, potently and selectively binds to STAT5 over STAT3, inhibits STAT5-SH2 doma
Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein
Cumaraswamy, Abbarna A.,Lewis, Andrew M.,Geletu, Mulu,Todic, Aleksandra,Diaz, Diego B.,Cheng, Xin Ran,Brown, Carla E.,Laister, Rob C.,Muench, David,Kerman, Kagan,Grimes, H. Leighton,Minden, Mark D.,Gunning, Patrick T.
, p. 1202 - 1206 (2015/10/05)
We herein report the design and synthesis of the first nanomolar binding inhibitor of STAT5 protein. Lead compound 13a, possessing a phosphotyrosyl-mimicking salicylic acid group, potently and selectively binds to STAT5 over STAT3, inhibits STAT5-SH2 doma
Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules
Fletcher, Steven,Page, Brent D.G.,Zhang, Xialoei,Yue, Peibin,Li, Zhi Hua,Sharmeen, Sumaiya,Singh, Jagdeep,Zhao, Wei,Schimmer, Aaron D.,Trudel, Suzanne,Turkson, James,Gunning, Patrick T.
, p. 1459 - 1470 (2012/07/01)
More than 50 new inhibitors of the oncogenic Stat3 protein were identified through a structure-activity relationship (SAR) study based on the previously identified inhibitor S3I-201 (IC50=86μM, Ki>300μM). A key structural feature of
